| arsenic trioxide / Generic mfg. |
JALSG-APL219R, JRCTs041190101: Radiotherapy combined with Toripalimab in the treatment of stage I/II extranodal nasal NK/T cell lymphoma with poor response to chemotherapy: a single-arm, multicenter study |
|
|
| Recruiting | N/A | 39 | Japan | Amnolake (tamibarotene) - Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma, arsenic trioxide - Generic mfg., Mylotarg (gemtuzumab ozogamicin) - UCB, PDL, Pfizer | Dokkyo Medical University Saitama Medical Center | Relapsed acute promyelocytic leukemia | | | | |
ChiCTR-ONC-13003444: Multicenter, prospective, and non-randomized investigation on efficacy and safety of a newly designed treatment protocol for newly diagnosed acute promyelocytic leukemia patients |
|
|
| Completed | N/A | 60 | | 1. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), till achievement of morphological complete remission (not less than 28 days); 2. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 ;4. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 5. DA regimen: intravenous injection of Daunorubicin (45mg/m2/day) for 3 days plus cytarabine (200mg/day) for 7 days; 6. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intrav ;7. MA regimen: intravenous injection of Mitoxanetrone (10mg/day) for 3 days plus cytarabine (200mg/day) for 7 days; 8. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 9. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intraven ;10. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 11. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR. | 大连医科大学附属第二医院血液科; Level of the institution：, LiaoNing Project for Medicine Peak Construction (No.201112;2011-2013). 200,000 Yuan. | Acute Promyelocytic Leukemia | | | | |
ChiCTR-INR-17014000: Evaluation of the efficacy and safety of arsenic trioxide for the prevention of recurrence and metastasis after palliative resection of primary liver cancer under the MDT diagnosis and treatment model |
|
|
| Not yet recruiting | N/A | 120 | | arsenic trioxide ;common theray | Union Hospital, Tongji Medical College, Huazhong University; Union Hospital, Tongji Medical College, Huazhong University, raise independently | primary liver cancer | | | | |
NCT02133287: To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization |
|
|
| Active, not recruiting | N/A | 2000 | RoW | AVI® Arsenic trioxide drug eluting stent delivery system, Firebird2® sirolimus eluting stent system | Beijing AmsinoMed Medical Device Co., Ltd | Ischemic Heart Disease, Myocardial Ischemia, Coronary Disease, Acute Coronary Syndrome | 06/18 | 11/22 | | |
ChiCTR-INR-16009903: Synergistic effect of Arsenic Trioxide on TACE in patients with unresectable HCC |
|
|
| Not yet recruiting | N/A | 350 | | TACE(5-FU 1000mg/m2，DDP 85mg/m2,MMC 6mg/m2), every four weeks ;TACE(5-FU 1000mg/m2，DDP 85mg/m2,MMC 6mg/m2)+ATO 10mg/d i.v for 7 days, every four weeks | The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital, Nanjing Medical University, Natural Science Foundation of China (No.81572325) | Hepatocellular Carcinoma | | | | |
ChiCTR2000032269: Clinical trial of intravenous arsenic trioxide in the treatment of advanced refractory colorectal cancer carrying structural mutant p53 gene |
|
|
| Recruiting | N/A | 20 | | intravenous arsenic trioxide | Sir Run Run Shaw Hospital affiliated to Medical College of Zhejiang University; Sir Run Run Shaw Hospital affiliated to Medical College of Zhejiang University, Self-raised by the researchers | Colorectal Cancer | | | | |
NCT04489706: Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation |
|
|
| Recruiting | N/A | 20 | RoW | Arsenic trioxide for injection, Arsenic trioxide for injection，producted by Beijing SL Pharmaceutical Co., Ltd. | Ruijin Hospital | Ovarian Cancer, Endometrial Cancer | 11/21 | 11/22 | | |
NCT03096496: Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy |
|
|
| Active, not recruiting | N/A | 161 | Europe | QoL questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Promyelocytic Leukemia | 01/22 | 01/22 | | |
ChiCTR2000032694: Clinical study for combined chemotherapy with arsenic trioxide for stage III osteosarcoma |
|
|
| Not yet recruiting | N/A | 40 | | N/A | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, Applied research fund | Osteosarcoma | | | | |
ChiCTR1800017310: A randomized controlled trial for arsenic trioxide combined with ESHAP (etoposide+methylprednisolone+cytarabine+cisplatin) in the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma. |
|
|
| Recruiting | N/A | 58 | | Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4 ;Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4; ATO 10mg/d d1-14 | Tongji Hospital Affiliated to Tongji University School of Medicine; Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai Municipal Health Planning Commission clinical research fund project | ALK+ anaplastic large cell lymphoma | | | | |
ChiCTR2200065047: Retrospective study of realgar-indigo naturalis formula in the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia |
|
|
| Not yet recruiting | N/A | 20 | | N/A | PLA 967th Hospital; PLA 967th Hospital, Self-finance | Acute promyelocytic leukemia | | | | |
ChiCTR1800018418: Comparative study on the efficacy of transarterial chemoembolization with arsenic trioxide drug-eluting beads, doxorubicin or pirarubicin drug-eluting beads and iodine oil- arsenic trioxide emulsion in the treatment of unresectable liver cancer |
|
|
| Recruiting | N/A | 240 | | As2O3 drug-loading embolization microspheres in TACE ;doxorubicin or pirarubicin drug-eluting beads in TACE ;iodine oil-As2O3 in TACE | Department of Interventional medicine, the First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-financing | Unresectable liver cancer | | | | |
NCT06060132: Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection |
|
|
| Recruiting | N/A | 400 | RoW | Sodium arsenite chloride injection, arsenic trioxide | Qianfoshan Hospital | Adverse Reaction, Cardiotoxicity, Evaluation Study | 12/23 | 12/23 | | |
APL, NCT06450145: Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant |
|
|
| Recruiting | N/A | 15 | RoW | interferon α-2b, arsenic trioxide, venetoclax | Zhejiang Provincial People's Hospital, First Affiliated Hospital of Zhejiang University | Tumour | 12/25 | 12/25 | | |
NCT03751917: Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia |
|
|
| Recruiting | N/A | 100 | Europe | Arsenic Trioxide, ATRA+ATO | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Promyelocytic Leukemia | 12/24 | 12/24 | | |
ChiCTR2000031796: Clinical study for combined chemotherapy with arsenic trioxide for stage III osteosarcoma |
|
|
| Not yet recruiting | N/A | 60 | | Combined chemotherapy with arsenic trioxide | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, Applied research fund | Osteosarcoma | | | | |
NCT04897490: RWE of 1st Line Treatment With ATO/ATRA for Adult APL |
|
|
| Recruiting | N/A | 50 | RoW | Evaluation of first line treatment with ATO/ATRA outcome | Grupo Argentino de Tratamiento de la Leucemia Aguda | Promyelocytic Leukemia, Adult Acute | 07/26 | 12/26 | | |
